Psilocybin
Psyched Wellness’s Calm, First Legal Amanita Muscaria Extract, Arrives at Pop-up Grocer in NYC
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and…
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is thrilled to announce its debut at Pop-up Grocer, the revered hub for innovative and groundbreaking products. Starting December 15th, consumers in New York City will have the exclusive opportunity to experience the transformative benefits of Calm Extract at the Pop-up Grocer location.
Pop-up Grocer has built a reputation as a hotspot for discovering cutting-edge products, offering a curated selection of the latest trends and must-have items in the realm of food, wellness, and lifestyle. As a testament to its commitment to offering the best and most unique products, Pop-up Grocer has chosen Calm Extract as its latest addition.
“We are incredibly excited to bring Calm Extract to Pop-up Grocer in New York City. This opportunity allows us to introduce our innovative product to a discerning audience, made even more accessible with our recently reduced price. This partnership is about bringing balance within reach, inviting everyone to embrace calm amidst the city’s vibrant energy.”
-Del Mahabadi, International Marketing Manager at Psyched Wellness
The reduction in price for Calm extract, now at $34.95 USD at 30ml and $64.99 USD at 60ml, was a strategic move that came after a comprehensive year-long initiative focused on customer feedback, extensive market research, and rigorous testing of various pricing models.This reduction in price reflects the Company’s dedication to listening and responding to the needs of its valued customers.
Visit https://shop.psyched-wellness.com/ for more information about ordering the product directly.
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin6 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics6 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation5 days ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics5 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics6 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment